Hologic is planning to launch its new global endometrial ablation device at the upcoming AAGL conference in November.
Hologic has announced its plan to launch the NovaSure V5 global endometrial ablation (GEA) device for abnormal uterine bleeding at the upcoming American Association of Gynecologic Laparoscopists (AAGL) 50th Global Congress held virtually and in-person November 14-17 in Austin, Texas, according to a company press release.1
The NovaSure system was initially approved by the U.S. Food and Drug Administration in 2001 and has been used to treat over 3 million patients by 2018.2 The device is designed to support physician comfort and control, as well as the ability to adapt to different cervical canal sizes.
“The NovaSure V5 device is at the forefront of innovation, established on an unmatched 20-year history of success and updated based on customer feedback,” said Essex Mitchell, division president, GYN Surgical Solutions, Hologic. “By listening to physicians and using their feedback as a guide for new innovation, Hologic’s GYN Surgical Solutions division remains committed to putting physicians and the women they serve first. We are always striving to work in partnership with physicians to achieve better outcomes for women.”
The new NovaSure V5 includes updated features such as a cervical seal equipped with EndoForm technology to increase the sealing surface and adjust to a range of cervical canals and anatomical variability. In addition, the device contains AccuSheath markings to improve the confidence and accuracy of seating and fundal placement.
The new system also includes SureClear technology, a fluid removal system from Hologic that provides suction through the array by constant tissue contact while also removing ablation byproducts including vapor and fluid from the uterus.
"I have used NovaSure for 20 years and consider it the gold standard treatment for patients with menstrual disorders. Believing there was no needed room for improvement, the V5 enhanced cervical seal feature has exceeded my expectations,” said Kelli Miller, MD, the first physician to perform the GEA procedure with the new NovaSure V5 device. “The markings added to the sheath correspond with the uterine sound measurement, further reassuring me of accurate placement. Ultimately, every woman has unique anatomy, and the cervical seal contours to a range of cervical canals, providing an advanced treatment option. Best of all, the V5 device does not require a steep learning curve, allowing the improvements to be even more appreciated by the physician.”
More information on the new NovaSure V5 device can be found at hologic.com and will be on display in-person at booth #536 and virtually at the hybrid AAGL conference.